GGrantIndex
Sort

82,697 grants matching vaccine development

Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study

$908,642
Joshua Aiden Hill · Fred Hutchinson Cancer Center · U01 · FY2022 · CA

Immune Correlates of Protection from TB

$908,608
Deepak Kaushal · Texas Biomedical Research Institute · R01 · FY2019 · AI

Multivalent Vaccine for Viral Hemorrhagic Fever

$908,442
Thomas William Geisbert · University Of Texas Med Br Galveston · U01 · FY2010 · AI

Multivalent DNA vaccine-mediated protection against Tuberculosis

$908,439
David B. Weiner · Wistar Institute · R01 · FY2021 · AI

Optimizing Oral Pediatric HIV Vaccines to Prevent Breast Milk Transmission

$908,245
Kristina Abel · Univ Of North Carolina Chapel Hill · R01 · FY2016 · DE

The Generation and Maintenance of Human Memory B Cells

$908,236
Susan Pierce · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

Development of NHP Models for Infectious Pathogens of Man

$908,201
Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Defining Drivers of HPV-associated Carcinogenesis

$908,100
Paul F Lambert · University Of Wisconsin-Madison · R35 · FY2023 · CA

THE TEDDY STUDY - COLORADO CLINICAL CENTER

$907,793
Marian J. Rewers · University Of Colorado Denver · U01 · FY2012 · DK

Modulating Cancer Stem Cell Signaling in Thoracic Malignancies

$907,746
David Schrump · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

CD180 targeted immunotherapeutic for chronic HBV in HIV infected patients

$907,661
Deborah L. Fuller · University Of Washington · R56 · FY2019 · AI

Task 10/D13 Efficacy of Select Antibiotics Against Pneumonic Plague in NHPs

$907,645
Mary Bruce · Battelle Memorial Institute · N01 · FY2009 · AI

Novel Concepts for the Eradication of HIV

$907,484
Rafick-Pierre Sekaly · Vgti Florida · DP1 · FY2011 · DA

Novel Concepts for the Eradication of HIV

$907,484
Rafick-Pierre Sekaly · Vgti Florida · DP1 · FY2012 · DA

Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig

$907,386
Michael David Alpert · Emmune, Inc · R44 · FY2022 · AI

Core B: GMP Cell and RNA Manufacturing

$907,314
Bruce L. Levine · University Of Pennsylvania · P01 · FY2018 · CA

HIV-1 Fusion Peptide-directed Vaccine Design Using Virus-like Particles

$907,275
Rui Kong · Emory University · R01 · FY2022 · AI

In vivo CRISPR engineering of B cells to produce anti-HIV broadly neutralizing antibodies using novel nanoparticles

$907,227
Jennifer Eileen Adair · Fred Hutchinson Cancer Center · R01 · FY2023 · AI

Vascular macrophages and T cells in atherosclerosis

$907,152
Klaus F. Ley · La Jolla Institute For Immunology · R35 · FY2021 · HL

Cooperative Center for the study of HCV antibody responses and vaccine antigens

$907,122
Mansun Law · Scripps Research Institute, The · U19 · FY2019 · AI

DCP - COPTRG - SELECT/PCPT

$907,044
Leonard Freedman · Leidos Biomedical Research, Inc. · N01 · FY2023 · CA

STING agonist-expressing BCG for bladder cancer

$907,018
Todd Wallach · Oncosting Llc · R44 · FY2022 · CA

Vascular macrophages and T cells in atherosclerosis

$906,991
Klaus F. Ley · La Jolla Institute For Immunology · R35 · FY2020 · HL

NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans

$906,964
Ruy M Ribeiro · Triad National Security, Llc · R01 · FY2023 · AI

Alphavirus Vaccines for Biodefense

$906,932
Scott C Weaver · University Of Texas Med Br Galveston · U54 · FY2012 · AI